Ibutilide


Generic Medicine Info
Contraindications
Concomitant use with class Ia (e.g. disopyramide, quinidine, procainamide) and other class III (e.g. amiodarone, sotalol) antiarrhythmic drugs or within 4 hours postinfusion of ibutilide.
Special Precautions
Patient with chronic atrial fibrillation. Correct electrolyte imbalance (particularly hypomagnesaemia and hypokalaemia) before administration and during therapy. Patient taking digoxin, particularly when plasma digoxin levels are confirmed or suspected to be above the usual therapeutic range. Not recommended in patients who previously had polymorphic ventricular tachycardia (e.g. torsades de pointes). Elderly. Pregnancy and lactation. Monitoring Parameters Monitor patient with continuous ECG for at least 4 hours after infusion or until QTc returned to baseline; electrolytes.
Adverse Reactions
Significant: Reversible or complete heart block; nonsustained ventricular tachycardia (monomorphic or polymorphic). Cardiac disorders: Supraventricular tachycardia, atrioventricular block, ventricular extrasystoles, bundle branch block, bradycardia, tachycardia, palpitations. Gastrointestinal disorders: Nausea. Nervous system disorders: Headache. Vascular disorders: Hypotension, hypertension.
Potentially Fatal: Arrhythmias, especially sustained polymorphic ventricular tachycardia, usually with QT prolongation or torsades de pointes but occasionally without documented QT interval prolongation.
Drug Interactions
May increase the risk of proarrhythmia with other agents known to prolong QT interval (e.g. TCAs, phenothiazines, tetracyclic antidepressants, H1-receptor antagonist antihistamines).
CIMS Class
Cardiac Drugs
ATC Classification
C01BD05 - ibutilide ; Belongs to class III antiarrhythmics.
Disclaimer: This information is independently developed by CIMS based on ibutilide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in